Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” [Breast 41S1 (2018) S11–12]

Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” [Breast 41S1 (2018) S11–12]

Bibliographic Details
Main Authors: Massimo Cristofanilli, Nadia Harbeck, Hope S. Rugo, Aurelio Castrellon, Anil Abraham Joy, Sunil Verma, Seock-Ah Im, Shrividya Iyer, Kathy Puyana Theall, Eric Gauthier, Xin Huang, Cynthia Huang Bartlett, Sibylle Loibl, Richard S. Finn
Format: Article
Language:English
Published: Elsevier 2020-02-01
Series:Breast
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977619311026

Similar Items

Similar Items